Nazari · Clinical therapeutics 2024 · umbrella meta-analysis of randomized controlled trials · n=?

The Effect of Berberine Supplementation on Glycemic Control and Inflammatory Biomarkers in Metabolic Disorders: An Umbrella Meta-analysis of Randomized Controlled Trials.

Cited 20 times in the scientific literature.

Level 1 - systematic review of randomized trials

Umbrella meta-analysis synthesizing existing meta-analyses of randomized controlled trials

PubMed 38016844 · doi:10.1016/j.clinthera.2023.10.019 · record verified 2026-08-27

What was done

An umbrella systematic review and meta-analysis was conducted by searching PubMed, Embase, Web of Science, Scopus, and Google Scholar up to April 2023. The authors aggregated findings from published meta-analyses of randomized controlled trials to assess the effect of berberine supplementation on glycemic indices and inflammatory biomarkers in adults with metabolic disorders.

What was found

Berberine supplementation led to statistically significant reductions across all assessed glycemic and inflammatory parameters: - Fasting blood glucose (FBG): WMD -0.77 (95% CI: -0.90 to -0.63); SMD -0.65 (95% CI: -0.83 to -0.47) - Hemoglobin A1C (HbA1C): WMD -0.57 (95% CI: -0.68 to -0.46) - Homeostasis model assessment for insulin resistance (HOMA-IR): WMD -1.04 (95% CI: -1.66 to -0.42); SMD -0.71 (95% CI: -0.97 to -0.46) - Insulin: WMD -1.00 (95% CI: -1.70 to -0.30); SMD -0.63 (95% CI: -0.94 to -0.32) - Interleukin-6 (IL-6): SMD -1.23 (95% CI: -1.61 to -0.85) - Tumor necrosis factor-alpha (TNF-α): SMD -1.04 (95% CI: -1.28 to -0.79) - C-reactive protein (CRP): WMD -0.62 (95% CI: -0.74 to -0.50); SMD -1.70 (95% CI: -2.21 to -1.19)

Why it matters

This umbrella review synthesizes inconsistent meta-analytic literature to confirm that berberine supplementation concurrently improves both glycemic control and systemic inflammation in individuals with metabolic disorders.

Limits

The abstract does not report the total number of included meta-analyses, primary randomized controlled trials, or overall sample size. Details regarding berberine dosage, treatment duration, specific metabolic diagnoses, adverse effects, and study overlap among meta-analyses are not provided.

Cited by